Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Capital Leases (2016 - 2017)

Historic Capital Leases for Neurocrine Biosciences (NBIX) over the last 8 years, with Q1 2017 value amounting to $544000.0.

  • Neurocrine Biosciences' Capital Leases fell 3275.65% to $544000.0 in Q1 2017 from the same period last year, while for Mar 2017 it was $544000.0, marking a year-over-year decrease of 3275.65%. This contributed to the annual value of $617000.0 for FY2016, which is 6032.15% down from last year.
  • As of Q1 2017, Neurocrine Biosciences' Capital Leases stood at $544000.0, which was down 3275.65% from $617000.0 recorded in Q4 2016.
  • Neurocrine Biosciences' 5-year Capital Leases high stood at $3.0 million for Q1 2013, and its period low was $544000.0 during Q1 2017.
  • Over the past 5 years, Neurocrine Biosciences' median Capital Leases value was $2.1 million (recorded in 2015), while the average stood at $1.8 million.
  • Per our database at Business Quant, Neurocrine Biosciences' Capital Leases surged by 3262.51% in 2013 and then tumbled by 6121.76% in 2016.
  • Quarter analysis of 5 years shows Neurocrine Biosciences' Capital Leases stood at $2.7 million in 2013, then decreased by 17.5% to $2.2 million in 2014, then dropped by 29.67% to $1.6 million in 2015, then plummeted by 60.32% to $617000.0 in 2016, then fell by 11.83% to $544000.0 in 2017.
  • Its last three reported values are $544000.0 in Q1 2017, $617000.0 for Q4 2016, and $649000.0 during Q3 2016.